Hematological diagnosis | N | Hb (g/dl) | Epo (mIU/ml) | log-Epo | RAI | p | p# |
x ± SD | Median (range) | x ± SD | x ± SD | ||||
Non anemic subjects | 54 | 13.9 ± 1.5 | 12.3 (3.7 - 30.9) | 1.10 ± 0.18 | 15.2 ± 2.3 | * |
|
Normal controls | 36 | 14.1 ± 1.2 | 13.6 (6.8 - 30.9) | 1.14 ± 0.16 | 16.1 ± 2.1 |
| * |
Diabetic non anemic subjects | 18 | 13.7 ± 1.1 | 10.4 (3.7 - 20.6) | 1.01 ± 0.21 | 13.7 ± 2.2 | <0.001 |
|
Secondary erythrocytosis | 34 | 17.5 ± 1.1 | 19.4 (11.5 - 90) | 1.33 ± 0.22 | 23.3 ± 4.2 | <0.001 | <0.001 |
Iron-deficiency anemia | 48 | 9.7 ± 1.5 | 54.1 (4.5 - 351) | 1.69 ±0.48 | 15.8 ± 3.3 | ns | ns |
Megaloblastic anemia | 56 | 7.7 ± 2.4 | 67.3 (9.4 - 280) | 1.81 ± 0.38 | 13.2 ± 2.3 | <0.001 | <0.001 |
Anemia of chronic disease | 34 | 10.4 ± 1.2 | 20.4 (6.6 - 102) | 1.33 ± 0.28 | 13.7 ± 2.4 | 0.028 | <0.001 |
Hemoglobinopathies | 115 | 9.6 ± 1.1 | 59.2 (4.7 - 450) | 1.80 ± 0.34 | 17.3 ± 3.3 | <0.001 | 0.046 |
β-thalassemic trait | 41 | 11.1 ± 1.4 | 17 (3.8 - 78.9) | 1.25 ± 0.26 | 13.8 ± 2.6 | 0.008 | <0.001 |
Aplastic anemia | 20 | 9.4 ± 2.9 | 300 (17.2 - 1567) | 2.29 ± 0.54 | 20.3 ± 3.6 | <0.001 | <0.001 |
Hemolytic & other anemias | 30 | 10.3 ± 1.8 | 34.9 (8.1 - 315) | 1.62 ± 0.47 | 16.2 ± 3.7 | ns | ns |
MDS-RA | 102 | 9.5 ± 1.7 | 93.7 (9.4 - 837) | 1.92 ± 0.45 | 17.7 ± 3.2 | <0.001 | 0.007 |
MDS-RARS | 46 | 9.0 ± 1.1 | 84.5 (15.3 - 587) | 2.00 ± 0.44 | 17.8 ± 3.2 | <0.001 | 0.009 |
MDS-RAEB | 92 | 9.1 ± 1.3 | 120 (13.1 - 1130) | 2.05 ± 0.44 | 18.4 ± 3.3 | <0.001 | <0.001 |
MDS-Other | 21 | 8.9 ± 1.1 | 174 (14.5 - 385) | 2.11 ± 0.44 | 18.5 ± 3.3 | <0.001 | <0.001 |
CMML and MDS/MPD | 65 | 9.7 ± 1.6 | 47.5 (12.2 - 455) | 1.77 ± 0.43 | 16.7 ± 2.7 | 0.003 | ns |
Polycythemia vera | 38 | 17.0 ± 1.7 | 6.6 (1.9 - 13.7) | 0.76 ± 0.22 | 12.8 ± 3.2 | <0.001 | <0.001 |
Essential thrombocythemia | 62 | 13.0 ± 2.2 | 12.9 (3.5 - 196) | 1.18 ± 0.35 | 14.9 ± 3.0 | ns | 0.034 |
Myelofibrosis | 32 | 9.4 ± 2.0 | 72.1 (7 - 2670) | 1.92 ± 0.56 | 17.0 ± 2.8 | 0.003 | ns |
Chronic myeloidleukemia | 18 | 10.6 ± 2.0 | 39.8 (11 - 201) | 1.61 ± 0.33 | 16.6 ± 2.6 | ns | ns |
Acute myeloidleukemia | 23 | 9.6 ± 2.2 | 48.6 (11.5 - 338) | 1.88 ± 0.48 | 17.2 ± 2.8 | 0.003 | ns |
Non Hodgkin’s lymphoma | 34 | 10.4 ± 2.2 | 31.6 (8.8 - 262) | 1.54 ± 0.35 | 15.6 ± 2.4 | ns | ns |
Chronic lymphoid leukemia | 30 | 11.7 ± 2.3 | 25.5 (8.0 - 288) | 1.48 ± 0.41 | 16.7 ± 2.2 | 0.008 | ns |
Plasma-cell dyscrasias | 79 | 9.7 ± 1.8 | 44.1 (8.0 - 326) | 1.65 ± 0.35 | 16.1 ± 3.3 | ns | ns |
Other lyphoprolif. disorders | 18 | 11.3 ± 2.7 | 30.3 (8.5 - 315) | 1.59 ± 0.44 | 17.1 ± 3.6 | 0.017 | ns |
|
|
|
|
|
|
|
|
Total subjects tested | 1096 | 10.6 ± 2.8 | 41.5 (2.3 - 2670) | 1.67 ± 0.52 | 16.6 ± 3.8 |
|
|